

# Gums and joints: is there a connection? Part one: epidemiological and clinical links

Isabel Lopez-Oliva,<sup>1</sup> Paola de Pablo,<sup>2</sup> Thomas Dietrich<sup>1</sup> and Iain Chapple\*<sup>1</sup>

## Key points

Suggests rheumatoid arthritis and periodontitis are epidemiologically linked.

Argues the effect of periodontal therapy in RA remains unknown and more rigorous clinical trials are needed.

Suggests rheumatologists and dentists should be aware of this link and work together for the benefit of the RA patient.

## Abstract

Rheumatoid arthritis (RA) and chronic periodontitis are common chronic inflammatory diseases that share numerous clinical and pathobiological characteristics. Due to their similarities, despite manifesting at anatomically distinct sites, the relationship between these two diseases has been investigated for many years. This review attempts to summarise the state of the field based on evidence published in the last ten years.

## Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that leads to the destruction of cartilage and bone in the joints. RA and chronic periodontitis are common chronic inflammatory diseases that share numerous clinical and pathobiological characteristics. The exacerbated immune reaction that arises in the gingival tissues of periodontitis patients leading to destruction of connective tissues and ultimately bone, is similar to the one occurring in the joints of RA patients.<sup>1</sup> Furthermore, these two diseases appear to be epidemiologically associated.<sup>2</sup> Due to their similarities, despite manifesting at anatomically distinct sites, the relationship between these two diseases has been investigated for many years.

The link between rheumatoid arthritis (RA) and periodontal disease (PD) dates back to Hippocrates who observed that the extraction of diseased teeth could cure arthritis. During the 1950s and 1960s the 'total dental clearance'

was commonly employed as part of the treatment regime for RA.<sup>3</sup> More recently, the upsurge in stratified medicine approaches to unravelling disease mechanisms has brought into focus the link between PD and RA. The international workshop between the European Federation of Periodontology and the American Academy of Periodontology in 2013 led to a call for more controlled clinical trials in this area and recommended an urgent need for research in this topic.<sup>4</sup> Since this workshop, a significant number of studies have investigated the PD-RA paradigm and this review attempts to summarise the state of the field based on evidence published in recent years.

### Prevalence of RA

The prevalence of RA in the first world is believed to be increasing, currently affecting about 1–2% of the world's population, with a male/female ratio of 1:3 and a peak incidence in the fourth to fifth decade of life. In the UK, the economic burden of RA is estimated to be more than £600 million,<sup>5</sup> and these patients often suffer from comorbidities, such as cardiovascular disease, which increases associated mortality.<sup>6</sup>

### Pathogenesis of RA

While the trigger for the autoimmune reaction that leads to RA remains unknown, our understanding of the pathogenesis of RA has increased substantially over the last

decade. The synovium of RA patients exhibits an elevated production of pro-inflammatory cytokines, including tumour necrosis factor (TNF), interleukins 1, 6, 15, 17 (IL), and granulocyte-macrophage colony-stimulating factor (GM-CSF). In the presence of these cytokines, T-cells and synoviocytes activate osteoclast maturation, which leads to bone resorption in the joint (Fig. 1). Moreover, the joint surface is encroached upon and destroyed by an anomalous fibrovascular coating, the pannus.<sup>7,8</sup> This constant state of inflammation and degradation of the joint structures causes chronic pain, fever, bone deformity, functional impairment and disability, classical features of inflammation.

### Diagnosis and treatment of RA

RA typically presents with swollen joints (often symmetrically), generalised pain, morning stiffness and movement limitations that last over an hour, and which can be reduced by gentle movements. These signs and symptoms help rheumatologists differentiate RA from osteoarthritis (OA), which is the most common form of joint disease, caused by cartilage degeneration and mechanical wear and tear. Interestingly, OA has not been found to be associated with chronic periodontitis and OA patients are frequently used as controls in studies that investigate the relationship between RA and PD.<sup>2,9,10</sup>

<sup>1</sup>Periodontal Research Group, Birmingham Dental School, 5 Mill Pool Way, Edgbaston, Birmingham, B5 7EG, UK;

<sup>2</sup>Institute of Inflammation and Ageing, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK.

\*Correspondence to: Iain Chapple  
Email: i.i.c.chapple@bham.ac.uk

Refereed Paper.

Accepted 21 August 2019

<https://doi.org/10.1038/s41415-019-0722-8>

The latest criteria employed for the diagnosis of RA were formulated in 2010 by the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR). This classification uses a score-based algorithm that considers type and number of joints involved, serological parameters (rheumatoid factor and anti-citrullinated protein antibodies/ACPAs), acute-phase reactants (C-reactive protein and erythrocyte sedimentation rate/ESR) and duration of symptoms.<sup>11</sup> While rheumatoid factor can be present in up to 20% of the general population, antibodies against citrullinated proteins (ACPA) are highly specific for RA. However, these antibodies are not present in all RA patients, therefore all clinical presentations of the criteria need to be considered necessary for the diagnosis of RA.<sup>12</sup>

The treatment of RA is complex and involves pharmacological and non-drug therapies including education, physical activity, occupational therapy and, in late disease, joint replacement. The aim of pharmacological treatment of RA is to relieve pain, reduce inflammation and prevent the destruction of cartilage and bone. This is usually achieved by the use of a combination of different drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids (oral or by injection), conventional disease-modifying anti-rheumatic drugs (DMARDs) and biological therapies, a subcategory of DMARDs which target specific steps of the inflammatory process, including TNF inhibitors, IL-6 inhibitors and anti-B-cell therapy.<sup>13</sup>

## Clinical evidence

### Epidemiological association between periodontitis and RA

For many years, studies have investigated the association between periodontitis, tooth loss and rheumatoid arthritis (Table 1). While two of these studies reported negative results, the majority have reported a higher risk and prevalence of periodontitis in rheumatoid arthritis patients and *vice versa*.<sup>20,23</sup>

Cross-sectional studies have shown that patients with RA have a significantly increased prevalence of periodontitis compared to systemically-healthy controls, with odds ratios (OR) ranging between 1.82 and 8.1.<sup>14,15</sup> Furthermore, patients with periodontitis have a higher prevalence of RA with OR ranging between 1.16 and 2.05.<sup>16,17</sup> Some of these studies, after adjusting for confounding factors, have demonstrated that the relationship




Fig. 1 Differences between the joint structure in rheumatoid arthritis and a healthy joint

appears independent of smoking,<sup>16</sup> oral hygiene (plaque),<sup>15,18</sup> and genetic factors.<sup>19</sup>

De Pablo *et al.* (2008) investigated this association using the National Health and Nutrition Examination Survey (NHANES), concluding that patients with RA had a higher prevalence of periodontitis (10–16%) compared to non-RA patients, with 50% of RA subjects identified as edentulous. Although the cause of tooth loss was unknown, the authors concluded that these edentulous patients may be representative of severe cases of periodontitis, as RA patients had a lower frequency of restorations and caries.<sup>14</sup>

In 2012 the European Federation of Periodontology (EFP) and American Academy of Periodontology (AAP) workshop on periodontal and systemic interrelationships concluded that the evidence of an association between RA and periodontitis was at least minimal but that more research was needed.<sup>4</sup> Since then, more than 150 papers have been published in the field, including a large number of reviews, animal studies and 18 cohort studies. The cohort studies were conducted in different countries around the world, some using very large data sets and only one reported no relationship.<sup>20</sup>

Using the Taiwanese National Health Insurance Research Database (NHIRD) cohort study which included 1,000,000 patients, a significant and independent association between RA and history of periodontitis was reported.<sup>21</sup> Another cohort study reported

that from the 74 RA patients examined, 94% suffered from moderate to severe periodontitis (48% moderate and 46% severe).<sup>22</sup>

In contrast, there are also studies that have not reported such associations. In a large prospective cohort study, using data reported from 91,132 nurses followed over 12 years, there was no evidence of a higher risk of developing RA among patients with periodontitis.<sup>23</sup> However, in this study, periodontitis was defined based on history of periodontal surgery through a self-reported questionnaire and no clinical examinations were conducted to diagnose periodontitis. More recently, no difference in the prevalence of periodontitis was observed in a Swedish case-control study including 2,740 RA patients. However, again in this study, periodontitis was investigated by self-reporting questionnaire.<sup>20</sup> Thus, these two studies may be biased due to the recruitment methodology, as no clinical examination was used to diagnose periodontitis and therefore their conclusions may be misleading.

The most recent systematic review and meta-analysis exploring the epidemiological evidence from eight case control studies, concluded that there is a strong and significant association between RA and PD. However, the authors highlight the need for further rigorous studies using consistent case definitions for periodontitis and a more defined population to avoid bias due to invalid control groups.<sup>24</sup>

Although some of these case control and cohort studies have clear limitations, there

**Table 1 Summary of observational studies published since 2000 (with study population >60) analysing the association between rheumatoid arthritis (RA) and periodontitis. Abbreviations as follows, OR: odds ratio; RR: risk ratio; PI: plaque index; GI: gingival index; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide**

| Author and year                                       | Study population  | Results  | Type of study               |
|---|---|--|-----------------------------|
| Mercado <i>et al.</i> , 2000 <sup>25</sup>            | 1,412 patients attending dental hospital                    | Periodontitis: higher prevalence of RA (3.95%)   | Cross-sectional             |
| Mercado <i>et al.</i> , 2001 <sup>18</sup>            | 65 patients (RA versus non-RA)                              | RA: higher number of missing teeth, deeper pockets. No difference in bleeding or plaque index                                  | Case control                |
| Marotte <i>et al.</i> , 2006 <sup>19</sup>            | 147 patients (RA)   | Association between periodontal bone loss and wrist bone destruction ( $\chi^2 = 11.82$ ) and shared epitope HLA-DR            | Cross-sectional             |
| De Pablo <i>et al.</i> , 2008 <sup>14</sup>           | 4,461 patients (NHANES III)                                 | RA: higher prevalence of periodontitis (OR:1.82), edentulous (OR:2.27), less decay ( $p < 0.001$ )                             | Cross-sectional             |
| Pischon <i>et al.</i> , 2008 <sup>15</sup>            | 109 patients (57 RA, 52 non-RA)                             | RA: higher prevalence of periodontitis (OR:8.05), statistically significant after adjusting to confounding factors (PI, GI)    | Case control                |
| Dissick <i>et al.</i> , 2009 <sup>10</sup>            | 69 RA patients versus 35 osteoarthritis (controls) patients | RA: higher prevalence of periodontitis and more severe RA patients with periodontitis associated with RF positive and anti-CCP | Case control                |
| Arkema <i>et al.</i> , 2010 <sup>23</sup>             | 81,132 patients (Nurses' Health Study prospective cohort)   | No evidence of higher incidence of RA in periodontitis   | Cohort study                |
| Demmer <i>et al.</i> , 2011 <sup>17</sup>             | 9,702 patients (NHANES I)                                   | Periodontitis: higher prevalence of RA (OR:2.05)   | Cross-sectional             |
| Potikuri <i>et al.</i> , 2012 <sup>16</sup>           | 91 RA (DMARD naive, non-smokers) vs healthy controls        | RA: higher prevalence of periodontitis (OR:4.28)   | Case control                |
| Smit <i>et al.</i> , 2012 <sup>26</sup>               | 95 RA, 420 matched controls                                 | RA: higher risk of periodontitis (RR: 3.7)   | Cross-sectional             |
| Chen <i>et al.</i> , 2013 <sup>21</sup>               | 13,779 newly diagnosed RA, 137,790 non-RA                   | periodontitis: higher prevalence of RA (OR:1.16)   | Cohort study                |
| Monsarrat <i>et al.</i> , 2014 <sup>22</sup>          | 74 RA patients  | 94% of RA had periodontitis (48% moderate and 46% severe)  | Cross-sectional             |
| Eriksson <i>et al.</i> , 2016 <sup>20</sup>           | 2,740 RA cases and 3,942 non-RA                             | No difference in periodontitis prevalence between groups   | Case control                |
| Bello-Gualtero JM, <i>et al.</i> , 2016 <sup>27</sup> | 119 pre-RA; 48 early-RA; matched controls for both          | Significant association with periodontal disease and IgG against Pg  | Cross-sectional             |
| Choi IA, <i>et al.</i> , 2016 <sup>28</sup>           | 264 RA and 88 matched controls                              | Higher prevalence of periodontitis in RA   | Cross-sectional             |
| Ayravainen L, <i>et al.</i> , 2017 <sup>29</sup>      | 168 RA ad 168 matched healthy controls                      | RA patients had worse periodontal condition  | Cross-sectional             |
| Schmickler J, <i>et al.</i> , 2017 <sup>30</sup>      | 53 RA DMARDs; 28 RA unresponsive to DMARDs; 42 controls     | RA patients had worse periodontal condition  | Prospective follow-up study |
| Ouedraogo DD, <i>et al.</i> , 2017 <sup>31</sup>      | 43 RA; 86 controls  | Prevalence of periodontitis higher in RA   | Case control                |

are now a large number of studies including thousands of patients from all over the world reporting an association.

### Effects of periodontal treatment on RA

Due to its high prevalence, scientists believe that periodontitis may represent an important modifiable risk factor for RA incidence and severity. If proven, treatment of periodontitis could offer a relatively inexpensive and safe, non-pharmacological treatment with direct benefit for patients with RA.

To date, ten clinical studies and three systematic reviews have investigated the effect of periodontal therapy on RA, analysing different parameters. Their results suggest that the treatment of periodontitis may have a significant positive effect on RA severity

(Table 2).<sup>32,33</sup> However, most of the published studies are small, have short follow-up times following periodontal therapy, and investigate different outcome measures.

Due to the heterogeneity of design in the various studies connecting RA and periodontitis, only a few parameters could be included for meta-analysis in the first systematic review, considering the effects of treatment of periodontitis on RA outcomes, with ESR being the only parameter found to be significantly reduced following periodontal treatment.<sup>34</sup> Another systematic review considering those same four studies concluded that, although the RA 'disease activity score' based on the 28 joint count (DAS28), appeared to be consistently improved following periodontal therapy throughout the four trials, further RCTs

were needed.<sup>2</sup> The latest systematic review conducted by Caldeloro included four studies from 2005 to 2013, and the authors concluded that there was a significant reduction of DAS28 following periodontal therapy.<sup>35</sup> Since then, three studies have been published, all of them reporting a significant improvement of RA parameters after periodontal therapy.<sup>36,37,38</sup>

Although these results are promising, some authors have failed to observe this effect. In a case report of one RA patient undergoing periodontal treatment for 15 years, no beneficial effect was reported.<sup>39</sup> Pinho *et al.* conducted a clinical trial in which they observed no reduction in acute phase reactants following periodontal therapy in RA, and systemic markers of inflammation did not correlate with observed improvements

**Table 2 Clinical trials evaluating the effect of periodontal therapy in rheumatoid arthritis (RA). Abbreviations as follows, PD: periodontitis; RA: rheumatoid arthritis; RF: rheumatoid factor, ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; DAS: disease activity score; VAS: visual analogue scale; TNF: tumour necrosis factor; CRP: C-reactive proteins; AAG: alpha-1 acid glycoprotein**

| Author and year                               | Duration | Patient number  | Parameters evaluated   | Results   |
|---|----------|---|--|---|
| Ribeiro <i>et al.</i> 2005 <sup>32</sup>      | 3 months | 42 RA + PD<br>16 periodontal treatment<br>26 oral hygiene and supragingival cleaning  | RF, ESR, HAQ   | ESR significantly reduced   |
| Al-Katma <i>et al.</i> 2007 <sup>43</sup>     | 8 weeks  | 29 RA + PD<br>17 periodontal treatment<br>12 no treatment   | DAS 28, ESR  | VAS, DAS 28 and ESR reduced   |
| Ortiz <i>et al.</i> 2009 <sup>44</sup>        | 8 weeks  | 40 RA + PD<br>10 periodontal treatment and DMARDs only<br>10 periodontal treatments and DMARDs with anti-TNF drugs<br>10 no periodontal therapy, DMARDs only<br>10 no periodontal treatment, DMARDs with anti-TNF drugs | ESR, TNF-alpha, signs and symptoms   | VAS and DAS 28 improved in treatment groups<br>ESR not significantly reduced<br>Anti-TNF drugs improved PPD and CAL |
| Pinho <i>et al.</i> 2009 <sup>40</sup>        | 6 months | 75 patients:<br>15 RA + PD with periodontal treatment<br>15 RA + PD no periodontal treatment<br>15 PD with periodontal treatment<br>15 PD no periodontal treatment  | DAS 28, CRP, ESR, AAG (alpha-1 acid glycoprotein)                              | No clear relation<br>AAG, ESR and CRP not significantly reduced with periodontal therapy                            |
| Okada <i>et al.</i> 2013 <sup>45</sup>        | 8 weeks  | 55 RA + PD<br>26 supragingival cleaning<br>29 no treatment  | DAS 28, CRP, anti-CCP, RF, TNF-alpha and levels of IgG to <i>P. gingivalis</i> | Reduction of DAS 28 and levels of IgG to <i>P. gingivalis</i> and citrulline  |
| Erciyas <i>et al.</i> 2013 <sup>33</sup>      | 3 months | 60 RA + PD<br>30 RA moderate-severe disease activity<br>30 RA low disease activity  | ESR, CRP, TNF-alpha, DAS28   | Significant reduction of ESR, CRP, TNF-alpha, DAS28   |
| Biyikoglu <i>et al.</i> 2013 <sup>46</sup>    | 6 months | 15 RA PD, 15 RA healthy   | DAS 28, GCF, serum IL-1 $\beta$ , TNF- $\alpha$                                | Significant decreases in DAS28 and gingival crevicular fluid interleukin-1  |
| Roman-Torres <i>et al.</i> 2015 <sup>36</sup> | 90 days  | 12 RA and 12 controls   | CRP and ESR  | Improvement after periodontal therapy (mild periodontitis)  |
| Khare <i>et al.</i> 2016 <sup>37</sup>        | 3 months | 60 RAPD patients  | DAS, ESR, CRP  | Significant improvement of DAS 28 and CRP after periodontal therapy   |
| Zhao <i>et al.</i> 2018 <sup>38</sup>         | 1 month  | 18 PD patients<br>18 RA patients<br>18 RA with PD patients<br>10 healthy controls   | anti-CCP, CRP, DAS 28, periodontal parameters                                  | Significant decrease of all RA parameters in treatment group  |

in periodontal health.<sup>40</sup> More recently, Kurgan reported a positive effect of periodontal treatment on gingival crevicular fluid (GCF) levels of a marker of systemic inflammation, plasminogen activator inhibitor-2, in 15 patients with periodontitis with or without rheumatoid arthritis but found no effect on RA parameters.<sup>41</sup>

Although in the workshop between the EFP and the AAP in 2013 it was concluded that more rigorous controlled clinical trials and research were needed in the field,<sup>4</sup> the studies published since the workshop continue to utilise a short follow-up period (ranging between eight weeks and six months) and a small sample size (<75 patients). Furthermore, each study employed different definitions of periodontitis and used different parameters to measure RA status, with the DAS28 score

being the most widely reported, based on subjective measures, such as the visual analogue scale (VAS) for pain and number of tender joints.

Therefore, although the current evidence suggests that there is an improvement in RA parameters after periodontal therapy, investigators in the field agree that longer and more rigorous randomised controlled trials are necessary to definitively determine the effects of periodontal treatment on RA.

Importantly, a recent systematic review considering the effect of periodontitis upon the response of RA patients to medication found that persistent periodontal inflammation hampers the effect of anti-TNF drugs.<sup>42</sup> Therefore, the treatment of periodontitis may also benefit the efficiency of pharmacological interventions in RA.

## Summary and conclusions

Numerous studies have reported an epidemiological link between RA and periodontitis and although some studies did not find such associations, the shortcomings of these studies may well explain their negative results. While numerous epidemiological studies conducted in the past have employed inconsistent definitions of periodontitis, the most recent studies have overcome this problem and also include larger numbers of patients. Therefore, considering the evidence, there appears to be a clear epidemiological relationship between RA and periodontitis.

Although there is sufficient evidence for an epidemiological link between RA and periodontitis, the directionality of this relationship is not known. Large-scale

longitudinal studies are needed to explore whether periodontitis increases the risk of incident RA and *vice versa*. Therefore, future research investigating the oral microbiome, inflammatory response and autoimmune response of patients at risk of developing RA, RA patients and periodontitis patients, is needed to clarify gaps in the literature.

While an increasing number of small clinical studies have shown a trend to an amelioration of surrogate measures of RA following periodontal treatment, controlled clinical trials with longer follow-up periods and larger numbers of patients are needed to corroborate this hypothesis. If proven, periodontal therapy could be a relatively inexpensive, non-pharmacological method of improving RA in addition to the known local and systemic benefits of maintaining periodontal health.

## References

- Koziel J, Mydel P, Potempa J. The link between periodontal disease and rheumatoid arthritis: an updated review. *Curr Rheumatol Rep* 2014; **16**: 408.
- Fuggle N R, Smith T O, Kaul A, Sofat N. Hand to mouth: a systematic review and meta-analysis of the association between rheumatoid arthritis and periodontitis. *Front Immunol* 2016; **7**: 80.
- Rothschild B. Correlation of periodontal disease with inflammatory arthritis in the time before modern medical intervention. *J Periodontol* 2017; **88**: 266–272.
- Linden G J, Herzberg M C, Working group 4 of joint EFP/ AAP workshop. Periodontitis and systemic diseases: a record of discussions of working group 4 of the Joint EFP/ AAP Workshop on Periodontitis and Systemic Diseases. *J Clin Periodontol* 2013; **40** (Spec Iss): S20–S23.
- Cross M, Smith E, Hoy D *et al*. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014; **73**: 1316–1322.
- Aviña-Zubieta J A, Choi H K, Sadatsafavi M, Etminan M, Esdaile J M, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Arthritis Rheum* 2008; **59**: 1690–1697.
- Firestein G S. Evolving concepts of rheumatoid arthritis. *Nature* 2003; **423**: 356–361.
- Niu X, Chen G. Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis. *J Immunol Res* 2014; 698192. DOI: 10.1155/2014/698192.
- Mikuls T R, Payne J B, Yu F *et al*. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. *Arthritis Rheumatol* 2014; **66**: 1090–1100.
- Dissick A, Redman R S, Jones M *et al*. Association of periodontitis with rheumatoid arthritis: a pilot study. *J Periodontol* 2010; **81**: 223–230.
- Aletaha D, Neogi T, Silman A J *et al*. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010; **62**: 2569–2581.
- van Gestel A M, Anderson J J, van Riel P L *et al*. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. *J Rheumatol* 1999; **26**: 705–711.
- Lipsky P E, van der Heijde D M, St Clair E W *et al*. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med* 2000; **343**: 1594–602.
- de Pablo P, Dietrich T, McAlindon T E. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. *J Rheumatol* 2008; **35**: 70–76.
- Pischon N, Pischon T, Kröger J *et al*. Association among rheumatoid arthritis, oral hygiene, and periodontitis. *J Periodontol* 2008; **79**: 979–986.
- Potikuri D, Dannana K C, Kanchinadam S *et al*. Periodontal disease is significantly higher in non-smoking treatment-naive rheumatoid arthritis patients: results from a case-control study. *Ann Rheum Dis* 2012; **71**: 1541–1544.
- Demmer R T, Molitor J A, Jacobs D R Jr, Michalowicz B S. Periodontal disease, tooth loss and incident rheumatoid arthritis: results from the First National Health and Nutrition Examination Survey and its epidemiological follow-up study. *J Clin Periodontol* 2011; **38**: 998–1006.
- Mercado F B, Marshall R I, Klestov A C, Bartold P M. Relationship between rheumatoid arthritis and periodontitis. *J Periodontol* 2001; **72**: 779–787.
- Marotte H, Farge P, Gaudin P, Alexandre C, Mouglin B, Miossec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. *Ann Rheum Dis* 2006; **65**: 905–909.
- Eriksson K, Nise L, Kats A *et al*. Prevalence of periodontitis in patients with established rheumatoid arthritis: a Swedish population based case-control study. *PLoS One* 2016; **11**: e0155956.
- Chen H H, Huang N, Chen Y M *et al*. Association between a history of periodontitis and the risk of rheumatoid arthritis: a nationwide, population-based, case-control study. *Ann Rheum Dis* 2013; **72**: 1206–1211.
- Monsarrat P, Vergnes J N, Blaizot A *et al*. Oral health status in outpatients with rheumatoid arthritis: the OSARA study. *Oral Health Dent Manag* 2014; **13**: 113–119.
- Arkema E V, Karlson E W, Costenbader K H. A prospective study of periodontal disease and risk of rheumatoid arthritis. *J Rheumatol* 2010; **37**: 1800–1804.
- Tang Q, Fu H, Qin B *et al*. A possible link between rheumatoid arthritis and periodontitis: a systematic review and meta-analysis. *Int J Periodontics Restorative Dent* 2017; **37**: 79–86.
- Mercado F, Marshall R I, Klestov A C, Bartold P M. Is there a relationship between rheumatoid arthritis and periodontal disease? *J Clin Periodontol* 2000; **27**: 267–272.
- de Smit M, Westra J, Vissink A, Doornbos-van der Meer B, Brouwer E, van Winkelhoff A J. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. *Arthritis Res Ther* 2012; **14**: R222.
- Bello-Gualtero J M, Lafaurie G I, Hoyos L X *et al*. Periodontal disease in individuals with a genetic risk of developing arthritis and early rheumatoid arthritis: a cross-sectional study. *J Periodontol* 2016; **87**: 346–356.
- Choi I A, Kim J H, Kim Y M *et al*. Periodontitis is associated with rheumatoid arthritis: a study with longstanding rheumatoid arthritis patients in Korea. *Korean J Intern Med* 2016; **31**: 977–986.
- Ayravainen L, Leirisalo-Repo M, Kuuliala A *et al*. Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population. *BMJ Open* 2017; **7**: e011916.
- Schmickler J, Rupprecht A, Patschan S *et al*. Cross-sectional evaluation of periodontal status and microbiologic and rheumatoid parameters in a large cohort of patients with rheumatoid arthritis. *J Periodontol* 2017; **88**: 368–379.
- Ouedraogo D D, Tiendrebeogo J, Guiguimde P L *et al*. Periodontal disease in patients with rheumatoid arthritis in Sub-Saharan Africa: a case-control study. *Joint Bone Spine* 2017; **84**: 113–114.
- Ribeiro J, Leao A, Novaes A B. Periodontal infection as a possible severity factor for rheumatoid arthritis. *J Clin Periodontol* 2005; **32**: 412–416.
- Erciyas K, Sezer U, Üstün K *et al*. Effects of periodontal therapy on disease activity and systemic inflammation in rheumatoid arthritis patients. *Oral Dis* 2013; **19**: 394–400.
- Kaur S, Bright R, Proudman S M, Bartold P M. Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. *Semin Arthritis Rheum* 2014; **44**: 113–122.
- Calderaro D C, Corrêa J D, Ferreira G A *et al*. Influence of periodontal treatment on rheumatoid arthritis: a systematic review and meta-analysis. *Rev Bras Reumatol Engl Ed* 2017; **57**: 238–244.
- Roman-Torres C V, Neto J S, Souza M A, Schwartz-Filho H O, Brandt W C, Diniz R E. An evaluation of non-surgical periodontal therapy in patients with rheumatoid arthritis. *Open Dent J* 2015; **9**: 150–153.
- Khare N, Vanza B, Sagar D, Saurav K, Chauhan R, Mishra S. Nonsurgical periodontal therapy decreases the severity of rheumatoid arthritis: a case-control study. *J Contemp Dent Pract* 2016; **17**: 484–488.
- Zhao X, Liu Z, Shu D *et al*. Association of periodontitis with rheumatoid arthritis and the effect of non-surgical periodontal treatment on disease activity in patients with rheumatoid arthritis. *Med Sci Monit* 2018; **24**: 5802–5810.
- Zhang X, Zhang J C. Combined therapy in a patient with generalized aggressive periodontitis and rheumatoid arthritis: a 15-year follow up case. [Chinese] *Zhonghua Kou Qiang Yi Xue Za Zhi* 2010; **45**: 279–282.
- Pinho Mde N, Oliveira R D, Novaes A B Jr, Voltarelli J C. Relationship between periodontitis and rheumatoid arthritis and the effect of non-surgical periodontal treatment. *Braz Dent J* 2009; **20**: 355–364.
- Kurgan S, Önder C, Balci N *et al*. Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy. *J Periodontol Res* 2017; **52**: 574–581.
- Savioli C, Ribeiro A C, Fabri G M *et al*. Persistent periodontal disease hampers anti-tumour necrosis factor treatment response in rheumatoid arthritis. *J Clin Rheumatol* 2012; **18**: 180–184.
- Al-Katma M K, Bissada N F, Bordeaux J M, Sue J, Askari A D. Control of periodontal infection reduces the severity of active rheumatoid arthritis. *J Clin Rheumatol* 2007; **13**: 134–137.
- Ortiz P, Bissada N F, Palomo L *et al*. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumour necrosis factor inhibitors. *J Periodontol* 2009; **80**: 535–540.
- Okada M, Kobayashi T, Ito S *et al*. Periodontal treatment decreases levels of antibodies to Porphyromonas gingivalis and citrulline in patients with rheumatoid arthritis and periodontitis. *J Periodontol* 2013; **84**: e74–e84.
- Biyikoglu B, Buduneli N, Aksu K *et al*. Periodontal therapy in chronic periodontitis lowers gingival crevicular fluid interleukin-1beta and DAS28 in rheumatoid arthritis patients. *Rheumatol Int* 2013; **33**: 2607–2616.